CI&T CINT 深 滬
已收盤 08-07 16:00:00 美东时间
3.56
+0.050
+1.42%
華盛通- 最 高3.60
- 今 開3.50
- 成交量 5.03万股
- 最 低 3.50
- 昨 收 3.51
- 總市值 4.79亿
- 52周最高 5.88
- 市盈率 靜 11.70
- 換手率 0.04%
- 52周最低 3.03
- 委 比 -69.23%
- 總股本 1.35亿
- 歷史最高 22.50
- 量 比 0.63
- 振 幅 2.85%
- 歷史最低 3.03
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Wedbush Downgrades CI&T to Neutral, Lowers Price Target to $4
Wedbush analyst Steven Wahrhaftig downgrades CI&T (NYSE:CINT) from Outperform to Neutral and lowers the price target from $7 to $4.
07-21 21:29
CI&T与Mistral达成战略合作，推动企业AI部署
全球AI部署合作伙伴CI&T本周宣布与法国开源AI模型公司Mistral建立多年期战略合作关系。根据协议，CI&T将作为Mistral在拉丁...
07-16 03:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
TD Cowen Maintains Buy on CI&T, Lowers Price Target to $6
TD Cowen analyst Bryan Bergin maintains CI&T (NYSE:CINT) with a Buy and lowers the price target from $8 to $6.
07-10 00:25
Shares of IT service-related companies are trading higher amid possible sympathy with Snowflake following its Q1 financial results and agentic AI agreement with AWS. Also, strength may be a result of optimism surrounding continued U.S.-Iran negotiations.
Shares of IT service-related companies are trading higher amid possible sympath...
05-29 03:07
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Wedbush Maintains Outperform on CI&T, Lowers Price Target to $7
Wedbush analyst Steven Wahrhaftig maintains CI&T (NYSE:CINT) with a Outperform and lowers the price target from $9 to $7.
05-12 21:20
CI&T Raises FY2026 Sales Guidance from $548.000M-$568.000M to $555.800M-$575.300M vs $561.409M Est
CI&T (NYSE:CINT) raises FY2026 sales outlook from $548.000 million-$568.000 million to $555.800 million-$575.300 million vs $561.409 million estimate.
05-12 04:17
CI&T Q2 Revenue expected to be more than $140.000M vs $138.317M Est
CI&T (NYSE:CINT) Q2 Revenue expected to be more than $140.000M vs $138.317M Est
05-12 04:17
